Yumanity Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.84 Insider Own2.40% Shs Outstand9.25M Perf Week11.92%
Market Cap10.56M Forward P/E- EPS next Y-4.97 Insider Trans-5.40% Shs Float7.56M Perf Month-10.81%
Income-39.50M PEG- EPS next Q-0.99 Inst Own27.80% Short Float1.45% Perf Quarter-9.40%
Sales8.00M P/S1.32 EPS this Y82.20% Inst Trans0.23% Short Ratio0.25 Perf Half Y-75.86%
Book/sh3.15 P/B0.36 EPS next Y-16.90% ROA- Target Price27.67 Perf Year-91.75%
Cash/sh1.89 P/C0.60 EPS next 5Y- ROE- 52W Range0.95 - 16.89 Perf YTD-61.43%
Dividend- P/FCF- EPS past 5Y37.80% ROI-102.20% 52W High-93.24% Beta0.89
Dividend %- Quick Ratio1.90 Sales past 5Y-0.80% Gross Margin- 52W Low20.17% ATR0.13
Employees40 Current Ratio1.90 Sales Q/Q-71.40% Oper. Margin- RSI (14)45.77 Volatility10.32% 10.33%
OptionableYes Debt/Eq0.10 EPS Q/Q- Profit Margin- Rel Volume0.07 Prev Close1.14
ShortableYes LT Debt/Eq0.00 EarningsMar 24 AMC Payout- Avg Volume433.08K Price1.14
Recom1.70 SMA20-1.55% SMA50-13.84% SMA200-76.18% Volume0 Change0.00%
May-12-22 04:45PM  
Mar-24-22 04:15PM  
Feb-18-22 12:16PM  
Feb-17-22 08:30AM  
Feb-04-22 06:48PM  
Jan-19-22 07:30AM  
Jan-11-22 08:00AM  
Jan-05-22 04:05PM  
Jan-04-22 08:00AM  
Dec-03-21 06:00PM  
Nov-16-21 04:30PM  
Nov-15-21 07:30AM  
Nov-12-21 04:05PM  
Nov-10-21 07:00AM  
Oct-14-21 07:00AM  
Sep-09-21 04:15PM  
Aug-16-21 07:00AM  
Aug-12-21 04:15PM  
Aug-06-21 07:00AM  
Jun-14-21 07:00AM  
May-27-21 07:00AM  
May-17-21 04:05PM  
May-13-21 07:00AM  
May-12-21 08:00AM  
May-04-21 08:00AM  
Apr-28-21 08:07PM  
Apr-22-21 07:00AM  
Apr-13-21 08:00AM  
Apr-06-21 08:00AM  
Mar-31-21 08:48AM  
Mar-23-21 09:41AM  
Mar-09-21 08:00AM  
Mar-02-21 04:05PM  
Feb-10-21 08:00AM  
Jan-06-21 08:00AM  
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Peters RichardPresident and CEOMar 28Sale1.8510,71519,775115,708Mar 30 04:05 PM
Mohsen PaulashChief Business OfficerFeb 03Sale1.831,9583,58359,135Feb 07 04:05 PM